Highlights of US CDER drug safety activity in 2003

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2004年 / 1005卷 / 1期

关键词：

Public Health; Medication Error; Product Testing; Drug Evaluation; Prescription Medicine;

D O I：

10.2165/00128415-200410050-00005

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 50 条

[1] CDER drug safety priorities 2023
Reactions Weekly, 2024, 1997 (1) : 2 - 2
[2] US FDA report highlights ongoing drug safety initiatives
Reactions Weekly, 2018, 1700 (1) : 2 - 2
[3] US FDA Report Highlights Ongoing Drug Safety Initiatives
不详
PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 298 - 298
[4] Institute of Medicine report calls for extensive overhaul of drug safety procedures at FDA, CDER
不详
FORMULARY, 2006, 41 (11) : 607 - +
[5] FDA plan highlights drug safety efforts
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (05) : 408 - 408
[6] Drug safety communication: highlights from ISoP
Reactions Weekly, 2011, 1374 (1) : 3 - 4
[7] International symposium on food safety highlights US commitment
不详
JOURNAL OF SWINE HEALTH AND PRODUCTION, 2010, 18 (01): : 34 - 34
[8] Adverse drug reactions in Canada - Program highlights as of April 2003
不详
CANADIAN FAMILY PHYSICIAN, 2003, 49 : 787 - 787
[9] CDER proposes changes to improve safety of compounding
Reactions Weekly, 2013, 1454 (1) : 4 - 4
[10] 2003 highlights
Hunter, D
CHEMICAL WEEK, 2003, 165 (46) : 5 - 5

← 1 2 3 4 5 →